Introduction {#s1}
============

Colorectal cancer (CRC) with distant metastasis is one of the main causes of death. About 20% of CRC patients are diagnosed with distant metastasis at initial diagnosis and 50--60% will eventually have metastases ([@B1], [@B2]). The CRC commonly metastasizes to liver, followed by lung, yet seldom to bone ([@B3]). Population-based studies have reported the incidence of BM is 3.0--10.4% in CRC patients ([@B4]--[@B6]), but previous autopsy findings have suggested incidence of up to 23.7% ([@B7]). The prognosis after BM detection is generally poor due to the advanced stage and the difficulty in treatment, with 5-year survival rate \< 5% ([@B8]). Median overall survival of CRC patients after BM diagnosis ranges from 5 to 22 months according to most researches ([@B4], [@B9]), with diverse factors affecting their prognosis such as some clinicopathological characteristics and provision of treatment. However, there is a lack of standard treatment guideline for BM from CRC at present. The possible therapies for BM include systemic therapy, local therapy and supportive treatment, with purpose to prevent skeletal-related events (SREs) like sever bone pain, hypercalcemia, spinal cord compression and pathological fracture and improve the survival of patients.

Synchronous BM (SBM) in CRC patients is relatively rare while most BMs occur metachronously after a length of follow-up time or during palliative treatment for other metastases. Generally, the patients with metachronous BM (MBM) have received systematic clinical intervention before the osseous lesion development, whereas those with SBM are mostly naive. Therefore, SBM and MBM from CRC may represent distinct clinicopathological characteristics, therapeutic sensitivity and outcomes, which require different treatment strategies. Many reports are controversial on the outcomes of synchronous and metachronous metastases from CRC, and most of which agree about the more aggressive clinical and pathological features of synchronous metastases ([@B10]--[@B14]). However, few studies in specifically exploring the differences between SBM and MBM from CRC have been reported.

Thus, the aims of our study were to (1) compare the clinicopathological characteristics of SBM and MBM from CRC; (2) compare the treatment modalities for SBM and MBM from CRC; (3) explore outcomes and prognostic factors of CRC patients with SBM and MBM, especially the impact of various treatment modalities on their prognosis, which would be helpful in modifying clinical management.

Materials and Methods {#s2}
=====================

Data Resources and Study Population
-----------------------------------

CRC patients who were diagnosed with BM between January 2008 and December 2017 at Chinese National Cancer Center, were retrospectively identified. The primary CRC lesion was confirmed by histopathological examination. The American Joint Committee on Cancer (AJCC) TNM stage and BM were identified by histopathological or imaging examinations such as standard X-rays, whole-body bone scans, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT). SBM refers to BM found within 3 months after the diagnosis of CRC, while MBM refers to BM found more than 3 months after the diagnosis of CRC ([@B15], [@B16]). For the number of BM, two adjacent vertebral metastases were classified into the solitary bone involvement, while non-consecutive metastases or more than 2 consecutive vertebral metastases were classified as multiple bone involvement. The time of follow-up was calculated from the BM diagnosis to death or January 2020. The cancer specific survival (CSS) was defined as the time from the BM diagnosis until cancer-associated death or the end of follow up. This study was approved by the Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences.

Prognostic Factors
------------------

Clinicopathological data and treatment methods were collected from medical records or via telephone follow-ups. Common variables were analyzed including age, gender, basic disease, primary tumor location, pathological type of tumor, tumor grade, carcinoembryonic antigen (CEA) levels at BM diagnosis, carbohydrate antigen199 (CA199) levels at BM diagnosis, alkaline phosphatase (ALP) levels at BM diagnosis, bone involvement, Karnofsky performance scores (KPS) at BM diagnosis, extra-osseous metastases, primary tumor resection, systemic treatment for BM, bisphosphonates for BM, radiotherapy for BM and operation for BM. Besides, AJCC TNM stage at initial diagnosis and time until BM were additionally evaluated for MBM. The basic disease was defined as other long-term or chronic coexisting diseases the BM patients from CRC suffered from, which affected basic metabolism or immune function of patients, mainly including hypertension, diabetes, heart disease, hepatitis, tuberculosis, autoimmune diseases, etc.

Statistical Analysis
--------------------

The comparison of clinicopathological characteristics and treatments between patients with SBM and MBM was done using χ2-test or Fisher\'s exact test where appropriate. The CSS was assessed with Kaplan-Meier method, with the log-rank tests used to compare subgroups. In order to reduce the selection bias, variables with *p* \< 0.10 by univariate Kaplan-Meier analysis were selected first, then a forward stepwise selection was performed using the selected variables in multivariable COX regression analysis. The independent prognostic factor was defined as the variable with *p* \< 0.05 by COX regression. Hazard ratio (HR) and corresponding 95% confidence interval (CI) were also calculated by multivariable COX analysis. All statistical analyses were performed with SPSS version 25.0 for Mac. It is considered as statistically significant when *p* \< 0.05.

Results {#s3}
=======

Finally, in total of 201 patients diagnosed with BM from CRC entered in our final analysis after excluding 31 cases who were not eligible ([Figure 1](#F1){ref-type="fig"}). 31.3% of patients (63/201) were identified with SBM at initial diagnosis while additional 68.7% of patients (138/201) developed MBM after diagnosis of CRC.

![The analytical cohort and exclusion criteria.](fonc-10-00974-g0001){#F1}

Patients Characteristics
------------------------

[Table 1](#T1){ref-type="table"} represented the clinicopathological characteristics of CRC patients with SBM and MBM. The median age of patients was 58 years (range 33--84) in SBM group and 59 years (range 19--79) in MBM group, respectively. CRC patients with SBM and MBM were similar with respect to their age at BM diagnosis (*p* = 0.974), gender (*p* = 0.459) and basic disease (*p* = 0.628). The rectal cancer was more common in MBM group (60.9%) than SBM group (41.3%), with statistical significance (*p* = 0.033). Patients with MBM were diagnosed more often with lower tumor grade (63.8 vs. 46.0%; *p* = 0.048) compared to those with SBM. Performances in CAE levels (*p* = 0.511), CA199 levels (*p* = 0.619), ALP levels (*p* = 0.827) and KPS (*p* = 0.631) at BM diagnosis between two groups were, respectively similar.

###### 

The comparison of clinicopathological characteristics in CRC patients with SBM and MBM.

  **Variable**                              **Synchronous**   **Metachronous**   ***p-*value**          
  ----------------------------------------- ----------------- ------------------ --------------- ------ ------------------------------------------
  **Age at BM diagnosis, years**                                                                        0.974
  \< 60                                     35                55.6               77              55.8   
  ≥ 60                                      28                44.4               61              44.2   
  **Gender**                                                                                            0.459
  Female                                    23                36.5               58              42.0   
  Male                                      40                63.5               80              58.0   
  **Basic disease**                                                                                     0.628
  No                                        37                58.7               86              62.3   
  Yes                                       26                41.3               52              37.7   
  **Primary tumor location**                                                                            0.033
  Rectum                                    26                41.3               84              60.9   
  Left hemicolon                            17                27.0               23              16.6   
  Right hemicolon                           20                31.7               31              22.5   
  **Pathological type of tumor**                                                                        0.054[^\*^](#TN1){ref-type="table-fn"}
  Adenocarcinoma                            56                88.9               128             92.8   
  Signet-ring cell carcinoma                4                 6.3                10              7.2    
  Others                                    3                 4.8                0               0.0    
  **Tumor grade**                                                                                       0.048[^\*^](#TN1){ref-type="table-fn"}
  Grade I, II                               29                46.0               88              63.8   
  Grade III, IV                             19                30.2               31              22.4   
  UK                                        15                23.8               19              13.8   
  **AJCC TNM stage at initial diagnosis**                                                               \<0.001[^\*^](#TN1){ref-type="table-fn"}
  I                                         0                 0.0                6               4.3    
  II                                        0                 0.0                14              10.2   
  III                                       0                 0.0                73              52.9   
  IV                                        63                100.0              41              29.7   
  UK                                        0                 0.0                4               2.9    
  **CEA levels at BM diagnosis**                                                                        0.511
  Negative                                  16                25.4               28              20.3   
  Positive                                  41                65.1               90              65.2   
  UK                                        6                 9.5                20              14.5   
  **CA199 levels at BM diagnosis**                                                                      0.619
  Negative                                  27                42.9               50              36.2   
  Positive                                  29                46.0               68              49.3   
  UK                                        7                 11.1               20              14.5   
  **ALP levels at BM diagnosis**                                                                        0.827
  Negative                                  47                74.6               102             73.9   
  Positive                                  14                22.2               29              21.0   
  UK                                        2                 3.2                7               5.1    
  **Bone involvement**                                                                                  \<0.001
  Solitary                                  58                92.1               51              37.0   
  Multiple                                  5                 7.9                87              63.0   
  **KPS at BM diagnosis**                                                                               0.631
  ≥ 80                                      49                77.8               103             74.6   
  \< 80                                     14                22.2               35              25.4   
  **Extra-osseous metastases**                                                                          0.959
  No                                        7                 11.1               15              10.9   
  Yes                                       56                88.9               123             89.1   
  **Time until BM**                                                                                     \-
  3 months−1 year                           \-                \-                 45              32.6   
  1--3 years                                \-                \-                 69              50.0   
  \>3 years                                 \-                \-                 24              17.4   

*No marks indicated the p-value was calculated by Chi-square test and an asterisk (^\*^) indicated the p-value was calculated by Fisher\'s test. CRC, colorectal cancer; SBM, synchronous bone metastasis; MBM, metachronous bone metastasis; N, number; UK, unknown; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen199; ALP, alkaline phosphatase*.

Patterns of BM and Extra-Osseous Metastasis
-------------------------------------------

Patients with MBM (63.0%) were significantly more involving multiple bone lesions compared to those with SBM (7.9%; *p* \< 0.001). Spine (65.1 vs. 73.2%) was the leading site of BM in SBM and MBM group, followed by pelvis (57.1 vs. 62.0%), long bones (34.9 vs. 22.6%) and ribs (30.2 vs. 21.9%).

There were 88.9% of patients (56/63) in SBM group and 89.1% of patients (123/138) in MBM group having extra-osseous metastases, respectively, with no significant difference (*p* = 0.959). The common extra-osseous sites were liver (61.9%), distant lymph nodes (54.0%) and lung (39.7%) in SBM patients. While lung (57.7%) was the most common extra-osseous metastatic site in MBM patients, followed by liver (45.7%) and lymph nodes (40.9%).

Treatments
----------

There were 85.5% of MBM patients (118/138) receiving primary tumor resection, which had been all performed at initial diagnosis. The proportions of primary tumor resection in MBM patients with AJCC stage I, II, III and IV were 100.0% (6/6), 100.0% (14/14), 97.3% (71/73), and 58.5% (24/41), respectively. Of the four patients with unknown AJCC TNM stage, three received this operation. In SBM group, only 25.4% of patients (16/63) underwent primary tumor resection because of the advanced stage.

All patients received palliative chemotherapy after BM diagnosis. There were 37.9% of cases in SBM group (25/63) and 39.1% of cases in MBM group (54/138; *p* = 0.941) receiving additional targeted therapy, respectively. The proportions of patients who received bisphosphonates treatment (60.3 vs. 55.8%; *p* = 0.548) or radiotherapy (77.8 vs. 68.8%; *p* = 0.192) were, respectively, similar between two groups. Only 2.2% of patients with MBM (3/138) underwent operative treatment for BM due to spinal cord compression while no patient with SBM received metastasectomy for BM (*p* = 0.541). The details were shown in [Table 2](#T2){ref-type="table"}.

###### 

The comparison of treatment strategies in CRC patients with SBM and MBM.

  **Variable**                                **Synchronous**                          **Metachronous**   ***p*-value**          
  ------------------------------------------- ---------------------------------------- ------------------ --------------- ------ --
  **Primary tumor resection**                 \<0.001                                                                            
  No                                          47                                       74.6               20              14.5   
  Yes                                         16                                       25.4               118             85.5   
  **Systemic treatment after BM diagnosis**   0.941                                                                              
  Chemotherapy alone                          38                                       60.3               84              60.9   
  Chemotherapy plus targeted therapy          25                                       39.7               54              39.1   
  **Bisphosphonates for BM**                  0.548                                                                              
  No                                          38                                       60.3               77              55.8   
  Yes                                         25                                       39.7               61              44.2   
  **Radiotherapy for BM**                     0.192                                                                              
  No                                          49                                       77.8               95              68.8   
  Yes                                         14                                       22.2               43              31.2   
  **Metastasectomy for BM**                   0.553[^\*^](#TN2){ref-type="table-fn"}                                             
  No                                          63                                       100.0              135             97.8   
  Yes                                         0                                        0.0                3               2.2    

*No marks indicated the p-value was calculated by Chi-square test and an asterisk (^\*^) indicated the p-value was calculated by Fisher\'s test. CRC, colorectal cancer; SBM, synchronous bone metastasis; MBM, metachronous bone metastasis; N, number*.

Survival
--------

In total of 195 CRC patients (97.0%) died because of cancer during a median follow-up time of 11 (range 1--198) months, with 61 cases in SBM group and 134 cases in MBM group. And only one patient with MBM died due to other disease. Median CSS was both 11 months for patients with SBM and MBM. The median interval time from CRC diagnosis to MBM was 18.5 months. [Figure 2](#F2){ref-type="fig"} displayed the Kaplan-Meier curves of SBM and MBM group according to different situations. The overall CSS of patients with SBM and MBM was similar, with no significant difference (*p* = 0.556; [Figure 2A](#F2){ref-type="fig"}). The median CSS in MBM patients with AJCC stage I, II, III and IV at initial CRC diagnosis was 28, 21, 10, and 8 months, respectively, which also showed large differences compared to SBM patients **(***p* = 0.003; [Figure 2B](#F2){ref-type="fig"}). In addition, patients diagnosed with MBM \>3 years after CRC diagnosis had a similar CSS with SBM patients (*p* = 0.093; [Figure 2C](#F2){ref-type="fig"}).

![Kaplan-Meier curves for CSS of CRC patients with SBM and MBM according to different situations: **(A)** Overall CSS. **(B)** AJCC TNM stage at initial diagnosis. **(C)** Time until diagnosis of BM.](fonc-10-00974-g0002){#F2}

To elucidate the outcomes with various treatments in two groups, the Kaplan-Meier curves for SBM and MBM patients were, respectively, represented in [Figure 3](#F3){ref-type="fig"}. Patients who had underwent primary tumor resection at initial diagnosis in SBM or MBM group ([Figure 3A](#F3){ref-type="fig"}) both had a better survival. The CSS was no significantly different between patients with and without targeted therapy in both two groups ([Figure 3B](#F3){ref-type="fig"}). Bisphosphonates therapy was related to a better CSS in synchronous group ([Figure 3C](#F3){ref-type="fig"}) while radiotherapy for BM ([Figure 3D](#F3){ref-type="fig"}) was related to a better CSS in MBM group. Because only 3 patients took the osseous metastasectomy, the relationship between operation for BM and CSS was unclear.

![Kaplan-Meier curves for CSS of CRC patients in synchronous group (?) versus metachronous group (---) according to various treatments: **(A)** Primary tumor resection. **(B)** Systemic treatment after BM diagnosis. **(C)** Bisphosphonates for BM. **(D)** Radiotherapy for BM.](fonc-10-00974-g0003){#F3}

Prognostic Factors
------------------

[Table 3](#T3){ref-type="table"} showed the *p*-values obtained by univariate Kaplan-Meier analysis in SBM and MBM group, respectively. And the variables with *p* \< 0.10 were selected to be further analyzed. The independent prognostic factors (*p* \< 0.05) were finally identified by multivariable COX regression analysis. We found multiple bone involvement (HR: 4.38; 95%CI: 1.61--11.92; *p* = 0.002), KPS scores \<80 (HR: 2.74; 95%CI: 1.45--5.20; *p* = 0.004), primary tumor resection (HR: 0.48; 95%CI: 0.24--0.92; *p* = 0.028) and bisphosphonates (HR: 0.23; 95%CI: 0.12--0.43; *p* \< 0.001) were independent prognostic factors for SBM patients ([Figure 4A](#F4){ref-type="fig"}). While positive CA199 levels (HR: 1.92; 95%CI: 1.30--2.83; *p* = 0.001), primary tumor resection (HR: 0.50; 95%CI: 0.30--0.85; *p* = 0.010) and radiotherapy (HR: 0.53; 95%CI: 0.35--0.80; *p* = 0.002) were independent prognostic factors for MBM patients ([Figure 4B](#F4){ref-type="fig"}).

###### 

The univariate Kaplan-Meier analysis in CRC patients with SBM and MBM.

  **Variable**                                **Synchronous**   **Metachronous**                                                                  
  ------------------------------------------- ----------------- ------------------ -------------------------------------------- ---- ------------ ------------------------------------------
  **Age at BM diagnosis, years**                                                   0.564                                                          0.521
  \< 60                                       9                 8.2--9.8                                                        11   9.0--13.0    
  ≥ 60                                        11                7.9--14.1                                                       12   10.7--13.4   
  **Gender**                                                                       0.617                                                          0.705
  Female                                      10                7.7--12.3                                                       11   8.8--13.2    
  Male                                        11                8.3--13.7                                                       11   9.6--12.4    
  **Basic disease**                                                                0.494                                                          0.209
  No                                          11                9.2--12.8                                                       12   10.5--13.5   
  Yes                                         9                 6.0--12.0                                                       11   9.3--12.7    
  **Primary tumor location**                                                       0.990                                                          0.273
  Rectum                                      11                8.0--14.0                                                       12   10.3--13.7   
  Left hemicolon                              11                6.0--16.0                                                       11   7.9--14.1    
  Right hemicolon                             9                 9.5--12.5                                                       9    6.4--11.6    
  **Pathological type of tumor**                                                   0.766                                                          0.516
  Adenocarcinoma                              11                8.6--13.4                                                       11   9.8--12.2    
  Signet-ring cell carcinoma                  4                 1.1--6.9                                                        8    5.0--11.0    
  Others                                      8                 1.6--14.4                                                       NA   NA           
  **Tumor grade**                                                                  0.494                                                          0.539
  Grade I, II                                 13                9.0--17.0                                                       12   10.7--13.3   
  Grade III, IV                               9                 8.2--9.8                                                        8    5.9--10.1    
  UK                                          9                 5.2--12.8                                                       9    5.4--12.6    
  **AJCC TNM stage at initial diagnosis**                                          NA                                                             0.003[^\*^](#TN3){ref-type="table-fn"}
  I                                           NA                NA                                                              28   14.8--41.2   
  II                                          NA                NA                                                              21   8.2--33.8    
  III                                         NA                NA                                                              10   8.2--11.8    
  IV                                          11                9.6--12.4                                                       8    4.3--11.7    
  UK                                          NA                NA                                                              11   0.0--29.6    
  **CEA levels at BM diagnosis**                                                   0.139                                                          0.008[^\*^](#TN3){ref-type="table-fn"}
  Negative                                    11                7.1--14.9                                                       11   8.9--13.1    
  Positive                                    10                8.1--11.9                                                       11   9.2--12.8    
  UK                                          8                 0.0--16.4                                                       12   6.2--17.8    
  **CA199 levels at BM diagnosis**                                                 0.367                                                          \<0.001[^\*^](#TN3){ref-type="table-fn"}
  Negative                                    11                7.6--14.4                                                       13   9.0--17.0    
  Positive                                    9                 8.0--10.0                                                       8    6.5--9.5     
  UK                                          13                0.2--25.8                                                       12   6.2--17.8    
  **ALP levels at BM diagnosis**                                                   0.023[^\*^](#TN3){ref-type="table-fn"}                         0.024[^\*^](#TN3){ref-type="table-fn"}
  Negative                                    11                7.6--14.4                                                       12   10.9--13.1   
  Positive                                    8                 5.6--10.4                                                       8    2.7--13.3    
  UK                                          4                 NA                                                              10   4.9--15.1    
  **Bone involvement**                                                             0.001[^\*^](#TN3){ref-type="table-fn"}                         0.034[^\*^](#TN3){ref-type="table-fn"}
  Solitary                                    11                8.9--13.1                                                       15   10.4--19.6   
  Multiple                                    5                 3.9--6.1                                                        10   8.0--12.0    
  **KPS at BM diagnosis**                                                          0.001**[^\*^](#TN3){ref-type="table-fn"}**                     0.446
  ≥ 80                                        11                8.1--13.9                                                       12   10.7--13.3   
  \<80                                        5                 1.3--8.7                                                        7    1.3--12.7    
  **Extra-osseous metastases**                                                     0.603                                                          0.224
  No                                          11                8.7--13.3                                                       12   5.4--18.6    
  Yes                                         10                8.2--11.8                                                       11   9.4--12.6    
  **Time until BM**                                                                NA                                                             0.063[^\*^](#TN3){ref-type="table-fn"}
  3 months−1 year                                               NA                                                              8    6.7--9.3     
  1--3 years                                                    NA                                                              12   10.4--13.6   
  \>3 years                                                     NA                                                              13   7.0--19.0    
  **Primary tumor resection**                                                      0.036[^\*^](#TN3){ref-type="table-fn"}                         0.001[^\*^](#TN3){ref-type="table-fn"}
  No                                          9                 7.0--11.0                                                       8    1.2--10.8    
  Yes                                         11                3.2--18.8                                                       12   10.7--13.3   
  **Systemic treatment after BM diagnosis**                                        0.454                                                          0.657
  Chemotherapy alone                          9                 7.8--10.2                                                       11   9.7--12.3    
  Chemotherapy plus targeted therapy          13                11.0--15.0                                                      11   8.8--13.2    
  **Bisphosphonates for BM**                                                       \<0.001[^\*^](#TN3){ref-type="table-fn"}                       0.095
  No                                          9                 8.0--10.0                                                       10   7.4--12.6    
  Yes                                         16                12.8--19.2                                                      12   10.3--13.7   
  **Radiotherapy for BM**                                                          0.058[^\*^](#TN3){ref-type="table-fn"}                         \<0.001[^\*^](#TN3){ref-type="table-fn"}
  No                                          9                 7.6--10.4                                                       10   8.1--11.9    
  Yes                                         11                5.5--16.5                                                       18   11.6--24.4   
  **Metastasectomy for BM**                                                        NA                                                             0.541
  No                                          NA                NA                                                              11   9.6--12.4    
  Yes                                         NA                NA                                                              21   5.0--37.0    

***An asterisk (^\*^)** indicated variables with p-value \< 0.10, which was selected into multivariable COX regression. CRC, colorectal cancer; SBM, synchronous bone metastasis; MBM, metachronous bone metastasis; CI, confidence interval; NA, not available; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen199; ALP, alkaline phosphatase*.

![Forest plots for CSS of CRC patients with SBM **(A)** or MBM **(B)** based on multivariable COX proportional hazard model.](fonc-10-00974-g0004){#F4}

Discussion {#s4}
==========

To our knowledge, this study is the first to retrospectively analyze the SBM and MBM together from CRC patients. The MBMs were more common, with incidence nearly twice higher than SBMs. The clinicopathological characteristics differed between two groups. The most striking finding was that in total of 63.0% of patients in MBM group had BMs to multiple sites, far more than those (7.9%) in SBM group. That might be because liver metastasis or lung metastasis from CRC in MBM group would have enough time to spread to skeletal systems by systemic circulation or directly invade chest bones such as sternum, rib and clavicle. We found there were similar therapeutic strategies between two groups, except that more MBM patients received the resection of primary tumor at initial diagnosis.

Colloca et al. ([@B14]) identified 425 CRC patients with distant metastases, discovering that the survival after metastasis diagnosis was shorter in synchronous group (18.5 vs. 62.8 months, *p* \< 0.001). Majority of reports consider synchronous metastases from CRC to be more aggressive than metachronous despite there is a controversy ([@B10]--[@B14]). In our study, the prognosis of BM was very poor, yet there was no significant difference in CSS between two groups ([Figure 2A](#F2){ref-type="fig"}). Several reasons might explain the similar outcomes. First, a significant percentage of patients with MBM had been treated with prior chemotherapy before BM diagnosis, while patients with SBM obviously were not and they were more chemo-naive chemo-sensitive ([@B13], [@B14]). Second, the multiple bone involvement was related to worse prognosis, which was more common in MBM group. Another possibility was that BMs was so aggressive that the timing of BM diagnosis had little impact on the outcome. In addition, patients with different time intervals to MBM diagnosis had similar CSS with SBM patients as [Figure 2C](#F2){ref-type="fig"} represented. However, it was difficult to interpret this result because the CSS of MBM patients significantly varied by different AJCC stages.

The clinical outcomes of patients with SBM and MBM appeared to be affected by different clinicopathological characteristics. We found CA199 levels was an independent prognostic factor only for MBM patients. But the CSS of patients with positive ALP levels was shorter in both two groups by univariate analysis, which was consistent with previous studies ([@B13]). So, careful surveillance in those indicators for patients with BM from CRC is recommended. Most researches have revealed the relationship between multiple BMs and worse prognosis ([@B17], [@B18]), while minority of studies have demonstrated the prognosis of CRC patients has no association with the number of BMs ([@B19]). In our study, multiple bone involvement was related to shorter survival. The median CSS of patients with multiple and solitary bone involvement was 5 and 11 months in SBM group (*p* \< 0.001) and 10 and 15 months in MBM group (*p* = 0.034), respectively. Therefore, systematic imaging examination is helpful to assess the outcome of BM.

The association between TNM stage and overall survival of CRC is generally confirmed ([@B20]). In our study, MBM patients with stage I at initial diagnosis had best prognosis with median CSS of 28 months, while it dramatically decreased to 8 months for those with stage IV (*p* = 0.003). Thus, strengthening early diagnosis of CRC and active treatment might also prolong the CSS even the BM was developed metachronously.

The prognosis of patients with SBM and MBM was also affected by distinct provision of treatment. As the rare metastatic disease, standard treatment guidelines for CRC patients with BM have not been established. Because all cases were treated with palliative chemotherapy after BM diagnosis in our study, the utility of chemotherapy in each group was unclear.

Bisphosphonates therapy can prevent the occurrence of osteolytic lesions and SREs caused by BM, which has become an effective treatment for bone pain and hypercalcemia ([@B21], [@B22]). Commonly used bisphosphonates such as pamidronate, zoledronic acid and ibandronate can be treated for BM patients in combination with conventional anti-tumor drugs. The difference in CSS of patients with and without bisphosphonates is significant only in SBM group, implying the sensitivity to bisphosphonates for SBM and MBM patients might exist difference.

Local treatments of CRC with BM include radiotherapy and surgery, etc. Previous researches have revealed radiotherapy can reduce bone pain and prevent pathological fracture or spinal cord compression ([@B23]--[@B25]). According to our study, median CSS of patients with palliative radiotherapy was significantly prolonged only in MBM group (18 vs. 10 months, *p* \< 0.001), which was also found to be one of independent prognostic factors for MBM patients. A meta-analysis of 1,026 cases from retrospective studies had suggested an improved survival for stage IV CRC patients with primary tumor resection ([@B26]). Another recent research enrolled 3,423 patients, reporting a poor prognosis for the patients with synchronous metastases who did not receive the resection of primary tumor ([@B27]). Despite these evidences, primary tumor resection has not been confirmed as a factor related to prolonged outcome of patients with unresectable synchronous metastases ([@B28], [@B29]). Our study showed that patients with primary tumor resection had significantly longer CSS in SBM group (11 vs. 9 months, *p* = 0.036), which was also an independent prognostic factor. This might be attributable to the reduction of tumor-related complications such as systemic inflammation, bleeding, obstruction and perforation. If advanced patients can tolerate the operation, active treatment for CRC is an alternative method for improving the survival of BM ([@B30]). Only 3 patients underwent operative treatment of BM due to spinal cord compression in our study and we could not evaluate its\' effect on outcome of patients. When non-operative treatment for pathological fracture, spinal instability or other complications caused by BM is invalid, surgical treatment for BM could be considered.

Our study had some limitations. First, this was a retrospective and single-center study, selection bias might occur. Second, the modest samples and non-randomized design limited the generalizability for the conclusions regarding optimal clinical management. Therefore, further prospective researches with randomized design, large sample and more clinical features are warranted.

Conclusion {#s5}
==========

Our study compared the clinical data and outcomes of SBM and MBM patients from CRC. Meanwhile, we identified favorable clinicopathological characteristics and treatments in SBM and MBM group, respectively. That could potentially guide physicians to treat patients with distinct clinical intervention and therapeutic strategies.
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